Serious interaction requiring monitoring; see WARNINGS section for detailed guidance.
Source: NLP:amitriptyline hydrochloride
Thyroid Interactions
Brand names: Thyroid
Route: Oral
FDA Black Box Warning
Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
Contraindications
CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone.
24 interactions on record
Thyroid hormones increase catabolism of vitamin K-dependent clotting factors, impairing compensatory increases in clotting factor synthesis. Patients stabilized on oral anticoagulants starting thyroid replacement require close monitoring and likely need anticoagulant dose reduction.
Source: NLP:thyroid, unspecified
Thyroid + AcarboseModerate
Thyroid products produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.
Source: NLP:acarbose
Thyroid + Cholestyramine LightModerate
Cholestyramine may delay or reduce the absorption of thyroid preparations.
Source: NLP:cholestyramine
Cholestyramine may delay or reduce the absorption of thyroid preparations.
Source: NLP:cholestyramine powder for suspension
Thyroid + Choleystyramine LightModerate
Cholestyramine may delay or reduce absorption of thyroid preparations.
Source: NLP:choleystyramine light
Thyroid + ColestipolModerate
Colestipol binds levothyroxine and liothyronine in the intestine, impairing absorption. Four to five hours should elapse between administration of colestipol and thyroid hormones.
Source: NLP:thyroid, unspecified
Produce hyperglycemia and may lead to loss of glycemic control when used with XIGDUO XR.
Source: NLP:dapagliflozin and metformin hydrochloride
Anti-thyroid drugs used with iodine supplementation may lead to hypothyroidism.
Source: NLP:doconexent, niacinamide, .alpha.-tocopherol acetate, dl-, cholecalciferol, beta carotene, ascorbic acid, thiamine mononitrate, riboflavin, pyridoxine hydrochloride, cyanocobalamin, iron, zinc oxide, cupric oxide, potassium iodide, magnesium oxide, folic acid, and levomefolate calcium
May produce hyperglycemia and lead to loss of glycemic control; monitor closely.
Source: NLP:empagliflozin, metformin hydrochloride
Thyroid + EstrogensModerate
Estrogens increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid glands on thyroid replacement may need increased thyroid doses.
Source: NLP:thyroid, unspecified
Thyroid + GlibenclamideModerate
Thyroid products may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.
Source: NLP:glyburide
Thyroid + GlipizideModerate
Thyroid products may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.
Source: NLP:glipizide
Thyroid products may produce hyperglycemia and lead to loss of blood glucose control. Patient should be closely observed for loss of blood glucose control.
Source: NLP:glipizide and metformin hcl
Thyroid products tend to produce hyperglycemia and may lead to loss of blood glucose control. Close observation required.
Source: NLP:glyburide and metformin hydrochloride
Thyroid + Insulin HumanModerate
Initiating thyroid replacement therapy may cause increases in insulin requirements. Patients receiving insulin should be closely monitored during thyroid replacement initiation.
Source: NLP:thyroid, unspecified
Thyroid products may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.
Source: NLP:linagliptin and metformin hydrochloride
Thyroid + MetforminModerate
Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.
Source: NLP:metformin
Thyroid + Metformin Er 500 MgModerate
May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.
Source: NLP:metformin er 500 mg
Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.
Source: NLP:metformin hydrochloride
May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.
Source: NLP:metformin hydrochloride extended-release tablets
May produce hyperglycemia and lead to loss of glycemic control when used with metformin.
Source: NLP:metformin hydrochloride tablet
Thyroid + Oral ContraceptivesModerate
Estrogen-containing oral contraceptives increase serum thyroxine-binding globulin, decreasing free levothyroxine. Patients without functioning thyroid glands may need increased thyroid doses.
Source: NLP:thyroid, unspecified
May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.
Source: NLP:sitagliptin and metformin hydrochloride